ogarawo.wordpress.com
“Creighton brings more than 12 year of experience in the commercial real estatew industryto Colliers,” says Doug Brandon, managiny principal for Colliers' Nashville office. “Wd are thrilled to have him onour Wright’s responsibilities will include the management of large institutionally owned health and medical as well as the growthb of the business line. Until March of this year, Wrighr was vice president of mixed-use development for Southerm Land Co., where he was responsiblde for the development of selecty realestate projects. Southern Land underwent a shift in executivse team makeup earlierthis year.
The Franklin-based developmentt company announced the appointments of Brian Sewell as presidentg and Chris Bove as CEO inearly February. Southerbn Land is the developeer of the Williamson County residentiaoprojects Westhaven, LaurelBrooke and The company also has projects in the Dallas/For Worth, Houston and Austin, Texas,
domingo, 30 de diciembre de 2012
sábado, 29 de diciembre de 2012
Report forced health-care changes - Business First of Buffalo:
takes-trendsthe.blogspot.com
A state commission created havoc for Westernj New York health care executives in late 2006 with a list of recommendations that included closing hospitals and mergint competinghealth systems. Two and a half years have passed sincer the State Commission on Healtyh Care Facilities in the 21st Centuryt made publicits report, which would come to be knowjn simply as the Berger Commission after its Some say the commission forced the beginningb of reform efforts, while others still have doubts on its One thing is Health care in the eight-county regioj has undergone sweeping change.
Arguably the most visiblee of those changes has been the creationhof , a unifying parent company formed after a year of intenss fighting between and Jody Lomeo, ECMC says the two organizations would never be whers they are today had it not been for the Bergere Commission. “They’ve inspired us to go from a competitivd situation to more of a collaborative situation and reallyu to finally takea good, hard look at what’s right for the communitu on a much largefr scale than just our individual institutions,” he James Kaskie, Kaleida president and CEO and presiden t of Great Lakes Health System, says the commission forced reforkm that was necessary.
Still, he says Western New York facex changes that other regions of the statde avoidedthrough politics. “A lot of marketw should have stepped up to the refornm effortand didn’t. That’s not true for Westerbn New York,” he Kaskie called the creation of Great Lakes Health one of the greatesr outcomes of theBerger Commission, helping to eliminate duplication and improver access. Next will come the joint creation of the GlobalVasculad Institute, followed by the closure of Millard Fillmorr Hospital – Gates Circle. “It’s just startingy a chain reaction of positive he says.
The Catholic Health System has implementedf all of the Berger Commission’s recommendations, including shuttering its Nazaretjh Nursing Home and avoiding a closurse at St. Joseph Hospital by transitioning it to a satellite campus of Sisters ofCharityh Hospital. But CHS officialsx caution against seeing Berger as a catalystfor “It wasn’t really says Dennis McCarthy, vice presidenft for public relations and governmeng affairs. “This was about capacity and about closing buildings and while some of that might have been worthy considering and part of an overalllreform plan, it’s only a piece of how you reform health care.
Many of the reformsa happening in health care now are more likelh a result of the economy and budgetary he says. “In the end, it’ws hard to say which. It’sx like a marble cake it’s hard to pull it out once it’ s mixed in,” McCarthy says. “Did Berger have an impact? Absolutely. Was it a good one? We don’t Others agree the jury’s still out on how the Berge recommendations will affect health Bruce Popper is vice presidentat , whichb represents 7,000 hospital workers at 14 facilities between Buffalo and the Southern Popper says the underlying premise of the commissio was that cutting excess capacity woulxd contain costs, but the reverse seems to be the SEIU’s Rochester facilities are under capacity and premiume are actually higher.
Sheila Kee, associate commissionerf for the stateHealth Department’s Westerhn Region, says the outcome of the Berger Commissiob goes way beyond simply cost savings. Organizationw are cooperating and working together in ways no one woul have imagined threeyears ago, includingh ECMC and Kaleida; and TLC Health Networkl to the south; and and to the north. “It’s beautiful to see she says. “Not only are they doinv that, but they’re thinking and they know there’s strengtbh in numbers. That’s the kind of things that lead to betterfhealth care.” “So is it perfect? Kee says. “Is it a major step forward?? Absolutely.
”
A state commission created havoc for Westernj New York health care executives in late 2006 with a list of recommendations that included closing hospitals and mergint competinghealth systems. Two and a half years have passed sincer the State Commission on Healtyh Care Facilities in the 21st Centuryt made publicits report, which would come to be knowjn simply as the Berger Commission after its Some say the commission forced the beginningb of reform efforts, while others still have doubts on its One thing is Health care in the eight-county regioj has undergone sweeping change.
Arguably the most visiblee of those changes has been the creationhof , a unifying parent company formed after a year of intenss fighting between and Jody Lomeo, ECMC says the two organizations would never be whers they are today had it not been for the Bergere Commission. “They’ve inspired us to go from a competitivd situation to more of a collaborative situation and reallyu to finally takea good, hard look at what’s right for the communitu on a much largefr scale than just our individual institutions,” he James Kaskie, Kaleida president and CEO and presiden t of Great Lakes Health System, says the commission forced reforkm that was necessary.
Still, he says Western New York facex changes that other regions of the statde avoidedthrough politics. “A lot of marketw should have stepped up to the refornm effortand didn’t. That’s not true for Westerbn New York,” he Kaskie called the creation of Great Lakes Health one of the greatesr outcomes of theBerger Commission, helping to eliminate duplication and improver access. Next will come the joint creation of the GlobalVasculad Institute, followed by the closure of Millard Fillmorr Hospital – Gates Circle. “It’s just startingy a chain reaction of positive he says.
The Catholic Health System has implementedf all of the Berger Commission’s recommendations, including shuttering its Nazaretjh Nursing Home and avoiding a closurse at St. Joseph Hospital by transitioning it to a satellite campus of Sisters ofCharityh Hospital. But CHS officialsx caution against seeing Berger as a catalystfor “It wasn’t really says Dennis McCarthy, vice presidenft for public relations and governmeng affairs. “This was about capacity and about closing buildings and while some of that might have been worthy considering and part of an overalllreform plan, it’s only a piece of how you reform health care.
Many of the reformsa happening in health care now are more likelh a result of the economy and budgetary he says. “In the end, it’ws hard to say which. It’sx like a marble cake it’s hard to pull it out once it’ s mixed in,” McCarthy says. “Did Berger have an impact? Absolutely. Was it a good one? We don’t Others agree the jury’s still out on how the Berge recommendations will affect health Bruce Popper is vice presidentat , whichb represents 7,000 hospital workers at 14 facilities between Buffalo and the Southern Popper says the underlying premise of the commissio was that cutting excess capacity woulxd contain costs, but the reverse seems to be the SEIU’s Rochester facilities are under capacity and premiume are actually higher.
Sheila Kee, associate commissionerf for the stateHealth Department’s Westerhn Region, says the outcome of the Berger Commissiob goes way beyond simply cost savings. Organizationw are cooperating and working together in ways no one woul have imagined threeyears ago, includingh ECMC and Kaleida; and TLC Health Networkl to the south; and and to the north. “It’s beautiful to see she says. “Not only are they doinv that, but they’re thinking and they know there’s strengtbh in numbers. That’s the kind of things that lead to betterfhealth care.” “So is it perfect? Kee says. “Is it a major step forward?? Absolutely.
”
jueves, 27 de diciembre de 2012
Private equity investors making cuts to survive - Washington Business Journal:
ogarawo.wordpress.com
, a consulting firm basecd in Bloomington, Minn., surveyed about 100 seniorf executives at privateequity firms. Respondents to the online survety cited aweak economy, the ability to meet businesz forecasts and the potential for loan defaults as theird major concerns for 2009. Respondentzs represented a cross section offund types, including buyou t funds (74 percent), mezzanine funds (13 and venture funds (12 percent). Fund size ranged from less than $100 milliob to more than $3 billion.
Facing today’s blealk dealmaking environment and a tightcredit market, privat equity firms have focused their resources on helping portfoliop companies acquire new customers and increase business with existinf customers. Legal matters, information technology and purchasing are areads receiving less attention from private equity executive sthis year. RSM McGladrey found that more than half of the funds represented in the survey have yet to close a dealin 2009.
Respondentds ranked “raising capital or acquisitiondebt (57 percent) and “decreasing values of acquisitioh targets due to declining performance” (25 percent) as the two biggesr obstacles to overcome when closing deals in 2009. While most of the surveye funds completed two to threw transactions per year in 2007and 2008, less than 20 percenrt expect to sell a portfolio companyh or product line this year. The survey confirmed that many private equity firmd are not looking to acquire new platform companies until theeconomy improves.
Rather, executives hope that they can weathe r the storm by managing the profitability of existinh investments until financing becomes morereadilu available. RSM McGladrey partnered with its global investmeny business to conductthe survey. It was compiled from Marchy 13 toApril 3.
, a consulting firm basecd in Bloomington, Minn., surveyed about 100 seniorf executives at privateequity firms. Respondents to the online survety cited aweak economy, the ability to meet businesz forecasts and the potential for loan defaults as theird major concerns for 2009. Respondentzs represented a cross section offund types, including buyou t funds (74 percent), mezzanine funds (13 and venture funds (12 percent). Fund size ranged from less than $100 milliob to more than $3 billion.
Facing today’s blealk dealmaking environment and a tightcredit market, privat equity firms have focused their resources on helping portfoliop companies acquire new customers and increase business with existinf customers. Legal matters, information technology and purchasing are areads receiving less attention from private equity executive sthis year. RSM McGladrey found that more than half of the funds represented in the survey have yet to close a dealin 2009.
Respondentds ranked “raising capital or acquisitiondebt (57 percent) and “decreasing values of acquisitioh targets due to declining performance” (25 percent) as the two biggesr obstacles to overcome when closing deals in 2009. While most of the surveye funds completed two to threw transactions per year in 2007and 2008, less than 20 percenrt expect to sell a portfolio companyh or product line this year. The survey confirmed that many private equity firmd are not looking to acquire new platform companies until theeconomy improves.
Rather, executives hope that they can weathe r the storm by managing the profitability of existinh investments until financing becomes morereadilu available. RSM McGladrey partnered with its global investmeny business to conductthe survey. It was compiled from Marchy 13 toApril 3.
miércoles, 26 de diciembre de 2012
Independent Care CEO exudes passion for patients - The Business Journal of Milwaukee:
ogarawo.wordpress.com
Since 1998, she has been workinvg with people eligible for Medicai d and Supplemental Security Income as presidenr and chief executive officer ofHealth Plan, a manage care plan in Milwaukee. "I've always been passionate about patienrt rights and treating peoplew with dignityand respect," 51, said. "Anywhere I can use my talents to make that happe nI will." Jerominski grew up in her father, Joseph Gruber, was vice presidenty of the AFL-CIO in Wisconsin. At 28, she ran for state Assembly againsta 20-year incumbent with a platform of educatingg people about then-new health maintenance organizations.
She lost by 35 but landed a legislativeclerk post, wher e she learned about the bureaucratic and funding side of healtjh care. Three years later, she was director of HMO programxs in Milwaukee for the state of Prior to joining Independent Jerominski was director of governmeng programsat , and contract manageer and manager of Medicaif for Blue Cross Blue Shield of Wisconsin. Independent Care is a jointr venture of Humana and the that was startes in October 1994 as the firstr company to offer managexd care for peoplewith disabilities.
It has abouty 6,000 members, or about 34 percent of the Milwaukeer County market who are eligible for a state-directed health insurance program for people who can'g afford medical care, said Bill Jensen, director of marketingb and compliance. Another 2,000 members are eligible for both Medicai dand Medicare, a federal healthg insurance program for those age 65 and over and some people with About half of its clients also have mental health and chronic substance abuse issues, Jerominski Like most managed care Independent Care works with providers to obtain volume discounts to streamlinew and manage costs of care for Jerominski estimates that the company has saved the state abouf $16 million since 1997.
But its size and specifi c market makethat difficult. "It's harder to achieved savings as asmaller HMO. Our only businesx is Medicaid SSI system," Jerominski said. "Our challenge is to try to negotiatee rates with providers forthis population." Of the company's 90 as many as 70 work face-to-face with members to ensure they get medicalo care and access to social services. To addresw the issue of patients not showinf upfor appointments, Independent Care transports patients to their visit and follows up to make sure they follow instructions, Jerominskui said.
"We've taken on a challenging population andenhanceed providers' ability to work with clients," Jerominski Independent Care's competitors include unit and , A Medicaid change in April pushed all Medicare-eligible people with access to a Medicaie HMO into managed care and boosted Independent Care's new enrollments from aboug 75 a month to as many as 700. Lee executive director of , a nonprofit service providet in Milwaukee for people with said Jerominski's experience working with the state and countty governments is one asset she bringss to his organization's board.
"Shs has practical as well as empathetic understanding of peopl e with disabilities and special Schulz said.
Since 1998, she has been workinvg with people eligible for Medicai d and Supplemental Security Income as presidenr and chief executive officer ofHealth Plan, a manage care plan in Milwaukee. "I've always been passionate about patienrt rights and treating peoplew with dignityand respect," 51, said. "Anywhere I can use my talents to make that happe nI will." Jerominski grew up in her father, Joseph Gruber, was vice presidenty of the AFL-CIO in Wisconsin. At 28, she ran for state Assembly againsta 20-year incumbent with a platform of educatingg people about then-new health maintenance organizations.
She lost by 35 but landed a legislativeclerk post, wher e she learned about the bureaucratic and funding side of healtjh care. Three years later, she was director of HMO programxs in Milwaukee for the state of Prior to joining Independent Jerominski was director of governmeng programsat , and contract manageer and manager of Medicaif for Blue Cross Blue Shield of Wisconsin. Independent Care is a jointr venture of Humana and the that was startes in October 1994 as the firstr company to offer managexd care for peoplewith disabilities.
It has abouty 6,000 members, or about 34 percent of the Milwaukeer County market who are eligible for a state-directed health insurance program for people who can'g afford medical care, said Bill Jensen, director of marketingb and compliance. Another 2,000 members are eligible for both Medicai dand Medicare, a federal healthg insurance program for those age 65 and over and some people with About half of its clients also have mental health and chronic substance abuse issues, Jerominski Like most managed care Independent Care works with providers to obtain volume discounts to streamlinew and manage costs of care for Jerominski estimates that the company has saved the state abouf $16 million since 1997.
But its size and specifi c market makethat difficult. "It's harder to achieved savings as asmaller HMO. Our only businesx is Medicaid SSI system," Jerominski said. "Our challenge is to try to negotiatee rates with providers forthis population." Of the company's 90 as many as 70 work face-to-face with members to ensure they get medicalo care and access to social services. To addresw the issue of patients not showinf upfor appointments, Independent Care transports patients to their visit and follows up to make sure they follow instructions, Jerominskui said.
"We've taken on a challenging population andenhanceed providers' ability to work with clients," Jerominski Independent Care's competitors include unit and , A Medicaid change in April pushed all Medicare-eligible people with access to a Medicaie HMO into managed care and boosted Independent Care's new enrollments from aboug 75 a month to as many as 700. Lee executive director of , a nonprofit service providet in Milwaukee for people with said Jerominski's experience working with the state and countty governments is one asset she bringss to his organization's board.
"Shs has practical as well as empathetic understanding of peopl e with disabilities and special Schulz said.
martes, 25 de diciembre de 2012
GM owes $9M to AK Steel - Dayton Business Journal:
exceeding-commissioner.blogspot.com
GM (NYSE: GM) owes the West Chester-based steelmaker (NYSE: AKS) roughly $9.1 million in trade debt, according to a list of GM’z 50 largest unsecured creditorx that was included with its initiapl bankruptcy courtfilings Monday. AK Steel Holding was listexd asthe company’s 33rd largest unsecured creditor. • , with $22.8 billio in bond debt; The International Union, Unite Automobile, Aerospace and Agricultural Implement Workerds ofAmerica — or — with $20.65 billion in employee obligations; and • , with $4.4 billionn in bond debt. The top 50 creditors have morethan $50 billion in claims.
Also as a part of its bankruptcgy filing, GM submitted a list of plants it will closror idle. GM’s local operations were not onthe list. a diesel engine producer that is a jointr venture between GM and Isuzu Motors is expected to keep its Moraineplant open. The plant stopped production May 18 for seven GM also operates a parts and service facilitty in West Chester that was not on the closure list. Three Ohio facilities were on the list a service and parts distribution center in Columbus closingv at the end ofthis year, a powertrain planft outside of Cleveland closing in Decemberr 2010 and a metal stampin plant in Mansfield set to clos e in June 2010.
GM (NYSE: GM) owes the West Chester-based steelmaker (NYSE: AKS) roughly $9.1 million in trade debt, according to a list of GM’z 50 largest unsecured creditorx that was included with its initiapl bankruptcy courtfilings Monday. AK Steel Holding was listexd asthe company’s 33rd largest unsecured creditor. • , with $22.8 billio in bond debt; The International Union, Unite Automobile, Aerospace and Agricultural Implement Workerds ofAmerica — or — with $20.65 billion in employee obligations; and • , with $4.4 billionn in bond debt. The top 50 creditors have morethan $50 billion in claims.
Also as a part of its bankruptcgy filing, GM submitted a list of plants it will closror idle. GM’s local operations were not onthe list. a diesel engine producer that is a jointr venture between GM and Isuzu Motors is expected to keep its Moraineplant open. The plant stopped production May 18 for seven GM also operates a parts and service facilitty in West Chester that was not on the closure list. Three Ohio facilities were on the list a service and parts distribution center in Columbus closingv at the end ofthis year, a powertrain planft outside of Cleveland closing in Decemberr 2010 and a metal stampin plant in Mansfield set to clos e in June 2010.
domingo, 23 de diciembre de 2012
Planet Opera: There is No Place Like Rome - WQXR Radio (blog)
sucujovide.wordpress.com
WQXR Radio (blog) | Planet Opera: There is No Place Like Rome WQXR Radio (blog) This month I heard both conductors at work in Rome. Muti conducted Simon Boccanegra for the first time in his career and it was the best Verdi performance I have ever heard him give. The overture began from total silence, as if from nothing, almost a ...
|
sábado, 22 de diciembre de 2012
Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
burdukovahycel.blogspot.com
These data were presented in one oral and two postefr presentations at the AmericanDiabetes Association's 69th Scientific Sessions in New Orleans, The oral presentation highlighted the significant improvements in eatintg control experienced by patients treated with Contrave versuxs placebo (p< 0.01), as well as previously reported resultx on the primary weight loss endpoints and measures of cardiometabolic risk.
"NB-302 resulte show that Contrave initiates and sustains weight loss and can improvew predictive markers for heart diseasew such aswaist circumference, triglycerides, HDL-cholesterol and hsCRP," said , Chief Medical Officer, Orexigen "Furthermore, due to its unique effectes on brain reward centers, Contrave may allow patientse to better control their eating potentially providing an important advantage to millions of Americana who struggle with obesity.
" The mood and weight-related quality of life findingds observed in the Contrave group were discusses in the oral presentation and reviewec in greater detail in the poster Contrave was not associated with suicidality or worsening of mood or depressivs symptoms, and in fact was associated with a decreased incidence of treatment-emergent depression compared to placebo. In Contrave patients achieved significantr improvements in overall quality oflife (p< and reported that benefits, such as improve physical function and self-esteem, occurres early in treatment and were maintained over one Results from the three other Phase 3 trials (NB-301, NB-304) are expected to be announced in the thire quarter of 2009.
Pending positive results, the Company is on track to submitt a New DrugApplication (NDA) with the FDA in the firstt half of 2010. NB-302 was a 56-week, double-blind, placebo-controllerd trial, conducted in 793 patients at nine U.S. The trial evaluated the additional weight loss ofContrave (32mtg naltrexone SR/360mg bupropion SR) when addes to an intensive behaviotr modification program consisting of counseling, diet and The co-primary endpoints were percenft change in total body weight from baselinde and proportion of patientsz who lost at least 5% of their baselined body weight.
Based on pre-specified intent-to-trea and completer analyses, obese patients treated with Contrave lost an averageof 20.3 pounde to 25.0 pounds, or 9.3% to 11.5% of theidr baseline body weight, versus 11.0 pounds to 16.0 or 5.1% to 7.3% of baselinee body weight, for patients treated with placebo. In in the categorical weight reduction analysis, the percentagw of patients who lost greate than or equalto 10% of their body weight was 41.5% in the Contrave group, compared to 20.2% in the placeb o group. Furthermore, 29.1% of patients lost greater than or equaloto 15% of their body weight in the Contravew group; compared to 10.
9% in the placebo All of these findingz were highly statistically significanyt (p< 0.001). "NB-302 demonstrates that Contraved delivers greater weight loss to patients when added to a rigorouws behavioral intervention program compared to the interventionprogramm alone, underscoring the important role of pharmacotherapy as part of a weighrt management program," said , President and Chief Executivr Officer, Orexigen Therapeutics. "These which we believe meet the FDA efficach guidance at the morestringent 10% also provide further suppor t of Contrave's potential as a weight loss treatment for clinicianw and their obese patients.
" The overall discontinuatio n rate due to adverse events in NB-3021 was 25.9% for patients taking Contrave versus 13.0% for thosee taking placebo. The most frequently observedd adverse events leading to discontinuatiomn for patients on study drug were urticaria (hives) and anxiety. Contrave was generally well with an overall safety profile consistenf with itsindividual components, naltrexonde and bupropion, two drugs that have been used separatelg for over 20 years. The discontinuation rate due to nauseazwas 4.6%.
This rate is lower than what was seen in the Phase 2trial (NB-201), which utilizedf the immediate release formulation of naltrexone as opposesd to the proprietary SR formulation used in this The most frequently observed treatment-emergentf adverse events for patients on studh drug were nausea, headache, constipation and Contrave is an investigational oral weight loss medication with a uniqude mechanism of action that works at two levelw within the central nervous system: one associaterd with controlling the balance of food intakre and metabolism and another involved in controlling food preference, rewarr and cravings.
We believe that Contraves may be the first treatmeng for obesity to target thesre reward centers in the centralnervoues system. Based on clinical trials completed to Contrave is believed to initiate and sustainm significant weight loss over one year of treatmentg byreducing appetite, increasing metabolis and allowing the body to continue losinvg weight by offsetting its natural tendency to fight back and slow down the weight loss Orexigen Therapeutics, Inc.
is a biopharmaceuticapl company focused on the treatment of The Company's lead combination product candidates targeted for obesity are which is in Phase 3 clinical and Empatic(TM), which is in the later stage of Phase 2 clinical Each product candidate is designed to act on a specififc group of neurons in the centra l nervous system with the goal of achieving appetitee suppression and sustained weight loss. Furthed information about the Company can be founat . Orexigen cautions you that statements includerd in this press release that are not a description of historicapl factsare forward-looking statements.
Words such as "believes,"" "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expression s are intended toidentify forward-looking statements. Thesde statements are based onthe Company's currentf beliefs and expectations. These forward-looking statementsd include statements regarding the efficacy and safetof Contrave, the enrollment, timing, execution and completion of clinical trials of the Company's product the potential for, and timinb of, an NDA submissionm for Contrave, and the potentiao to obtain regulatory approval for, and effectively treatr obesity with, Contrave and Empatic.
The inclusionj of forward-looking statements should not be regarded as a representationj by Orexigen that any of its plansw willbe achieved. Actual results may diffeer from those set forth in this releasee due to the risk and uncertaintiew inherent in theOrexigen including, without limitation: the final analyse s of data from the NB-302 trial and othe r clinical trials of Contrave may producer negative or inconclusive results, or may be inconsistent with previousl conducted clinical trials, and the FDA may not agreed with Orexigen's interpretation of efficacy and safety results; earlier clinical trials may not be predictive of future results; Contrave or Empatic may not receivs regulatory approval on a timely basis or at all, and the FDA may require Orexigen to complete additional clinical, non-clinical or othe r requirements prior to the submissioj or the approval of NDAs for either product candidate; the potentiakl for adverse safety findings relating to Contrave or Empa tic to delayy or prevent regulatory approval or or result in product liability the third parties on whom Orexigen reliexs to assist with the development programs for Contrave or including clinical investigators, contract clinical research organizations and manufacturing may not successfully carryh out their contractual duties or obligations or meet expected and the quality or accurachy of the data or materials generateed by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the abilityy of Orexigen and its licensors to obtain, maintainj and successfully enforce adequate paten t and other intellectual property protection of its product candidates; and othedr risks described in the Company's filings with the Securities and Exchang Commission.
You are cautioned not to place undude reliance onthese forward-looking statements, whicuh speak only as of the date and Orexigen undertakes no obligatiojn to revise or update this news releases to reflect events or circumstances afterd the date hereof. All forward-looking statementz are qualified in their entirety by thiscautionaryg statement. This caution is made under the safe harbod provisions of Section 21E of the Private Securities Litigation Reforkm Actof 1995. SOURCE Orexigen Therapeutics, Inc.
These data were presented in one oral and two postefr presentations at the AmericanDiabetes Association's 69th Scientific Sessions in New Orleans, The oral presentation highlighted the significant improvements in eatintg control experienced by patients treated with Contrave versuxs placebo (p< 0.01), as well as previously reported resultx on the primary weight loss endpoints and measures of cardiometabolic risk.
"NB-302 resulte show that Contrave initiates and sustains weight loss and can improvew predictive markers for heart diseasew such aswaist circumference, triglycerides, HDL-cholesterol and hsCRP," said , Chief Medical Officer, Orexigen "Furthermore, due to its unique effectes on brain reward centers, Contrave may allow patientse to better control their eating potentially providing an important advantage to millions of Americana who struggle with obesity.
" The mood and weight-related quality of life findingds observed in the Contrave group were discusses in the oral presentation and reviewec in greater detail in the poster Contrave was not associated with suicidality or worsening of mood or depressivs symptoms, and in fact was associated with a decreased incidence of treatment-emergent depression compared to placebo. In Contrave patients achieved significantr improvements in overall quality oflife (p< and reported that benefits, such as improve physical function and self-esteem, occurres early in treatment and were maintained over one Results from the three other Phase 3 trials (NB-301, NB-304) are expected to be announced in the thire quarter of 2009.
Pending positive results, the Company is on track to submitt a New DrugApplication (NDA) with the FDA in the firstt half of 2010. NB-302 was a 56-week, double-blind, placebo-controllerd trial, conducted in 793 patients at nine U.S. The trial evaluated the additional weight loss ofContrave (32mtg naltrexone SR/360mg bupropion SR) when addes to an intensive behaviotr modification program consisting of counseling, diet and The co-primary endpoints were percenft change in total body weight from baselinde and proportion of patientsz who lost at least 5% of their baselined body weight.
Based on pre-specified intent-to-trea and completer analyses, obese patients treated with Contrave lost an averageof 20.3 pounde to 25.0 pounds, or 9.3% to 11.5% of theidr baseline body weight, versus 11.0 pounds to 16.0 or 5.1% to 7.3% of baselinee body weight, for patients treated with placebo. In in the categorical weight reduction analysis, the percentagw of patients who lost greate than or equalto 10% of their body weight was 41.5% in the Contrave group, compared to 20.2% in the placeb o group. Furthermore, 29.1% of patients lost greater than or equaloto 15% of their body weight in the Contravew group; compared to 10.
9% in the placebo All of these findingz were highly statistically significanyt (p< 0.001). "NB-302 demonstrates that Contraved delivers greater weight loss to patients when added to a rigorouws behavioral intervention program compared to the interventionprogramm alone, underscoring the important role of pharmacotherapy as part of a weighrt management program," said , President and Chief Executivr Officer, Orexigen Therapeutics. "These which we believe meet the FDA efficach guidance at the morestringent 10% also provide further suppor t of Contrave's potential as a weight loss treatment for clinicianw and their obese patients.
" The overall discontinuatio n rate due to adverse events in NB-3021 was 25.9% for patients taking Contrave versus 13.0% for thosee taking placebo. The most frequently observedd adverse events leading to discontinuatiomn for patients on study drug were urticaria (hives) and anxiety. Contrave was generally well with an overall safety profile consistenf with itsindividual components, naltrexonde and bupropion, two drugs that have been used separatelg for over 20 years. The discontinuation rate due to nauseazwas 4.6%.
This rate is lower than what was seen in the Phase 2trial (NB-201), which utilizedf the immediate release formulation of naltrexone as opposesd to the proprietary SR formulation used in this The most frequently observed treatment-emergentf adverse events for patients on studh drug were nausea, headache, constipation and Contrave is an investigational oral weight loss medication with a uniqude mechanism of action that works at two levelw within the central nervous system: one associaterd with controlling the balance of food intakre and metabolism and another involved in controlling food preference, rewarr and cravings.
We believe that Contraves may be the first treatmeng for obesity to target thesre reward centers in the centralnervoues system. Based on clinical trials completed to Contrave is believed to initiate and sustainm significant weight loss over one year of treatmentg byreducing appetite, increasing metabolis and allowing the body to continue losinvg weight by offsetting its natural tendency to fight back and slow down the weight loss Orexigen Therapeutics, Inc.
is a biopharmaceuticapl company focused on the treatment of The Company's lead combination product candidates targeted for obesity are which is in Phase 3 clinical and Empatic(TM), which is in the later stage of Phase 2 clinical Each product candidate is designed to act on a specififc group of neurons in the centra l nervous system with the goal of achieving appetitee suppression and sustained weight loss. Furthed information about the Company can be founat . Orexigen cautions you that statements includerd in this press release that are not a description of historicapl factsare forward-looking statements.
Words such as "believes,"" "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expression s are intended toidentify forward-looking statements. Thesde statements are based onthe Company's currentf beliefs and expectations. These forward-looking statementsd include statements regarding the efficacy and safetof Contrave, the enrollment, timing, execution and completion of clinical trials of the Company's product the potential for, and timinb of, an NDA submissionm for Contrave, and the potentiao to obtain regulatory approval for, and effectively treatr obesity with, Contrave and Empatic.
The inclusionj of forward-looking statements should not be regarded as a representationj by Orexigen that any of its plansw willbe achieved. Actual results may diffeer from those set forth in this releasee due to the risk and uncertaintiew inherent in theOrexigen including, without limitation: the final analyse s of data from the NB-302 trial and othe r clinical trials of Contrave may producer negative or inconclusive results, or may be inconsistent with previousl conducted clinical trials, and the FDA may not agreed with Orexigen's interpretation of efficacy and safety results; earlier clinical trials may not be predictive of future results; Contrave or Empatic may not receivs regulatory approval on a timely basis or at all, and the FDA may require Orexigen to complete additional clinical, non-clinical or othe r requirements prior to the submissioj or the approval of NDAs for either product candidate; the potentiakl for adverse safety findings relating to Contrave or Empa tic to delayy or prevent regulatory approval or or result in product liability the third parties on whom Orexigen reliexs to assist with the development programs for Contrave or including clinical investigators, contract clinical research organizations and manufacturing may not successfully carryh out their contractual duties or obligations or meet expected and the quality or accurachy of the data or materials generateed by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the abilityy of Orexigen and its licensors to obtain, maintainj and successfully enforce adequate paten t and other intellectual property protection of its product candidates; and othedr risks described in the Company's filings with the Securities and Exchang Commission.
You are cautioned not to place undude reliance onthese forward-looking statements, whicuh speak only as of the date and Orexigen undertakes no obligatiojn to revise or update this news releases to reflect events or circumstances afterd the date hereof. All forward-looking statementz are qualified in their entirety by thiscautionaryg statement. This caution is made under the safe harbod provisions of Section 21E of the Private Securities Litigation Reforkm Actof 1995. SOURCE Orexigen Therapeutics, Inc.
viernes, 21 de diciembre de 2012
Albany Medical College benefits from $960K cancer society award - The Business Review (Albany):
sucujovide.wordpress.com
The grant will support the breast cancert reasearch being conductedby Dr. Ceshj Chen, in the Center for Cell Biology and Cancert Research atthe Albany, N.Y. medical It is the single largest grant ever presented by the Cancerr Society in the Albany Chen said breast cancer develops whencertaijn genes, called onocogenes, caused normal cells to transform into cancer He is attempting to "put a bullseye" on breast cancef by studying the behavior of an oncogene calledc WWP 1, which is active in over 40 percent of clinical tumof samples.
He and his colleagues have already demonstrated that inhibitionn of WWP1 retards thegrowth of, and even inducea death of, a subset of breastf cancer cells. "Our team's long-term goal is to see if WWP 1 gives off any unique molecular targets duringbreastg cancer," Dr. Chen said. "Once these targets could be used to develop new breasyt cancer testsand treatments."
The grant will support the breast cancert reasearch being conductedby Dr. Ceshj Chen, in the Center for Cell Biology and Cancert Research atthe Albany, N.Y. medical It is the single largest grant ever presented by the Cancerr Society in the Albany Chen said breast cancer develops whencertaijn genes, called onocogenes, caused normal cells to transform into cancer He is attempting to "put a bullseye" on breast cancef by studying the behavior of an oncogene calledc WWP 1, which is active in over 40 percent of clinical tumof samples.
He and his colleagues have already demonstrated that inhibitionn of WWP1 retards thegrowth of, and even inducea death of, a subset of breastf cancer cells. "Our team's long-term goal is to see if WWP 1 gives off any unique molecular targets duringbreastg cancer," Dr. Chen said. "Once these targets could be used to develop new breasyt cancer testsand treatments."
jueves, 20 de diciembre de 2012
Skybus founder launches another low-cost airline, JetAmerica - Triangle Business Journal:
inufyw.blogspot.com
In a bit of deja vu, John Weikle has startesd anotherdiscount airline, caller , with a similar model to Skybus, the companu he helped found but left before it went bankrupt in April 2008. Though the Triad is not on the list of six citiezs JetAmerica will start flying from onJuly 13, the regionb is on a list of futurew possible sites for passenge service. For now, service will be limitex to non-stop flights between Lansing, Mich.; Melbourne-Verlo Beach, Fla.; South Bend, Ind.; Toledo, Ohio; St. Minn.; and the New N.J., area. The company says it can offer lower fares because those airports are cheapert to serve with less competition from major which wasalso Skybus’ strategy.
Bryan a spokesman for which is basedin Fla., said Winston-Salem’s Smith Reynolds Airport and are both being considered, but decisions on future locations aren’t expected for another year to 18 JetAmerica is now advertisingy nine one-way, nonstop seats for $9 on -800 seriesx jets. Much like the no-frills Skybuw – which offered several similarly priced tickets perflighrt – checking bags, meals, beveragexs and in-flight television are The company will use airplanes leased from charter company Miami Air Glazer said.
JetAmerica has 22 corporate employees and will contracf out for gate crews and baggage The news comes a year aftedthe orange-and-white Skybus planes were grounded when the Columbus, Ohio-basex company went bankrupt. Skybus begahn flying out of PTI in May 2007 and made the airpory its second hub location nationally in early 2008 just months before it sunk undeer the weight ofsoaring jet-fuel costs, heavy debt loads and too littlr revenue from ticket sales.
Glazer said he was not involvedswith Skybus, but he added that Weikle left before the
In a bit of deja vu, John Weikle has startesd anotherdiscount airline, caller , with a similar model to Skybus, the companu he helped found but left before it went bankrupt in April 2008. Though the Triad is not on the list of six citiezs JetAmerica will start flying from onJuly 13, the regionb is on a list of futurew possible sites for passenge service. For now, service will be limitex to non-stop flights between Lansing, Mich.; Melbourne-Verlo Beach, Fla.; South Bend, Ind.; Toledo, Ohio; St. Minn.; and the New N.J., area. The company says it can offer lower fares because those airports are cheapert to serve with less competition from major which wasalso Skybus’ strategy.
Bryan a spokesman for which is basedin Fla., said Winston-Salem’s Smith Reynolds Airport and are both being considered, but decisions on future locations aren’t expected for another year to 18 JetAmerica is now advertisingy nine one-way, nonstop seats for $9 on -800 seriesx jets. Much like the no-frills Skybuw – which offered several similarly priced tickets perflighrt – checking bags, meals, beveragexs and in-flight television are The company will use airplanes leased from charter company Miami Air Glazer said.
JetAmerica has 22 corporate employees and will contracf out for gate crews and baggage The news comes a year aftedthe orange-and-white Skybus planes were grounded when the Columbus, Ohio-basex company went bankrupt. Skybus begahn flying out of PTI in May 2007 and made the airpory its second hub location nationally in early 2008 just months before it sunk undeer the weight ofsoaring jet-fuel costs, heavy debt loads and too littlr revenue from ticket sales.
Glazer said he was not involvedswith Skybus, but he added that Weikle left before the
martes, 18 de diciembre de 2012
Books that give a little more - Washington Post
belyaevostapuki.blogspot.com
Books that give a little more Washington Post People often ask for recommendations of good books for their financially trifling parent, adult child, sibling, cousin or friend. Yes, I said trifling. Many people are tired of supporting or enabling grown folks who are not handling their personal ... |
viernes, 14 de diciembre de 2012
Report: VC-backed liquidity drops to $8.2B in Q1, lowest since 2005 - Baltimore Business Journal:
martaemimbzini.blogspot.com
billion, the lowest quarterly totalk since the fourth quarterof 2005, accordingh to the a report Wednesday by . The largesy deal of the firs t quarter wasRound Texas-based Inc.'s (NASDAQ:DELL) $1.4 billion acquisition of Nashua, N.H.-basecd data-storage company Inc. The second largest deal of the firsrt quarter wasSanta Clara, Calif.-based Inc.'s $1 billion purchase of open-source database company Inc. of Calif. The report shows that the first quarter saw just80 M&q transactions completed, accounting for roughly $7.8 billion in liquidity, a far cry from the $10.2 billionm generated via 105 M&Asx in the first three months of 2007. Only six U.S.
venture-backed companiesz went public in thefirst quarter, raisingf just $392 million -- a 67 percent declinre from the $1.2 billion raised via 13 IPOs in the first quarted last year. Information technology companies accounted for the bulk of the capita raisedvia M&A, with 59 transactions generating more than $6.1 billion in liquidity, a 5 percentg dip for the segmenf from the $6.4 billion raised in 79 M&q transactions during the first quarter of 2007. By software companies accounted for the bulk of IT deal flow with29 M&A transactions completed, garnering nearly $2.3 billion.
The report said 14 venture-backecd health care companies completes M&As in the first quartere and raisedover $1.1 a nearly 42 percenyt drop-off from the $1.9 billion raise d in three fewer M&As for the segment during the firstf three months of 2007. The media n amount of venture capital raised priorto M&As rose to $24.i million and the median number of yearsz between initial equity funding and liquidity now stands at a record seven Four of the six venture-backed IPOs in the firstr quarter were for healthh care companies, which raised a disappointing $164 millioj collectively, according to the report.
The median amount raised at IPO in the firs quarter of 2008was $53 million, down 34 perceng from the $80 million median in the firs t quarter last year. The mediab amount of venture capital raised priore to IPO actually ticked down slightlhyto $56 million while the median time to IPO stretchef to nearly 8.3 years.
billion, the lowest quarterly totalk since the fourth quarterof 2005, accordingh to the a report Wednesday by . The largesy deal of the firs t quarter wasRound Texas-based Inc.'s (NASDAQ:DELL) $1.4 billion acquisition of Nashua, N.H.-basecd data-storage company Inc. The second largest deal of the firsrt quarter wasSanta Clara, Calif.-based Inc.'s $1 billion purchase of open-source database company Inc. of Calif. The report shows that the first quarter saw just80 M&q transactions completed, accounting for roughly $7.8 billion in liquidity, a far cry from the $10.2 billionm generated via 105 M&Asx in the first three months of 2007. Only six U.S.
venture-backed companiesz went public in thefirst quarter, raisingf just $392 million -- a 67 percent declinre from the $1.2 billion raised via 13 IPOs in the first quarted last year. Information technology companies accounted for the bulk of the capita raisedvia M&A, with 59 transactions generating more than $6.1 billion in liquidity, a 5 percentg dip for the segmenf from the $6.4 billion raised in 79 M&q transactions during the first quarter of 2007. By software companies accounted for the bulk of IT deal flow with29 M&A transactions completed, garnering nearly $2.3 billion.
The report said 14 venture-backecd health care companies completes M&As in the first quartere and raisedover $1.1 a nearly 42 percenyt drop-off from the $1.9 billion raise d in three fewer M&As for the segment during the firstf three months of 2007. The media n amount of venture capital raised priorto M&As rose to $24.i million and the median number of yearsz between initial equity funding and liquidity now stands at a record seven Four of the six venture-backed IPOs in the firstr quarter were for healthh care companies, which raised a disappointing $164 millioj collectively, according to the report.
The median amount raised at IPO in the firs quarter of 2008was $53 million, down 34 perceng from the $80 million median in the firs t quarter last year. The mediab amount of venture capital raised priore to IPO actually ticked down slightlhyto $56 million while the median time to IPO stretchef to nearly 8.3 years.
jueves, 13 de diciembre de 2012
Nypro Inc. Company Profile | Company Information
sucujovide.wordpress.com
Nypro is a plastics We operate 52 separate businesses in 17 countries that designplastics products, build molds used to mold plastics, perform the plasticsx injection molding, supply other parts needed to be assemblesd with plastics parts, assemble the parts and preparw them for delivery to our customeer or our customer's customer. Our customers are the world'ws largest companies who use plasticsx intheir products. They use us to make theirt products because we can do it faster and cheaper thananybody else. This web site illustratews our company.
It shows and tells how Nypro is what marketswe serve, the capabilities and technologies that we offer to our customers, and the news and industrgy activities that affect us. Nypro is one of the largesft employee-owned companies. It is ownedd by the people who make it tick at all As a customplastics molder, Nypro'sd first and overwhelming responsibilityu is to its customers. For the most part, we do not have our own producte - rather, we make our customers' products for them. Beingf able to offer customers a supplie company that is ownedc by the same people who providd its services is a hugecompetitivs advantage.
It means that Nypro people are prepared to offetra 24-hour commitment to your success. That is why our mottl is, "We'll be there with you."
Nypro is a plastics We operate 52 separate businesses in 17 countries that designplastics products, build molds used to mold plastics, perform the plasticsx injection molding, supply other parts needed to be assemblesd with plastics parts, assemble the parts and preparw them for delivery to our customeer or our customer's customer. Our customers are the world'ws largest companies who use plasticsx intheir products. They use us to make theirt products because we can do it faster and cheaper thananybody else. This web site illustratews our company.
It shows and tells how Nypro is what marketswe serve, the capabilities and technologies that we offer to our customers, and the news and industrgy activities that affect us. Nypro is one of the largesft employee-owned companies. It is ownedd by the people who make it tick at all As a customplastics molder, Nypro'sd first and overwhelming responsibilityu is to its customers. For the most part, we do not have our own producte - rather, we make our customers' products for them. Beingf able to offer customers a supplie company that is ownedc by the same people who providd its services is a hugecompetitivs advantage.
It means that Nypro people are prepared to offetra 24-hour commitment to your success. That is why our mottl is, "We'll be there with you."
miércoles, 12 de diciembre de 2012
Interim state budget in the works - Business First of Columbus:
ogarawo.wordpress.com
The office of Senate PresidentBill Harris, R-Ashland, said legislators are schedulefd to take up the state industrial commissiojn budget in the afternoon. Expected to be tacked onto that bill is an amendmenty that would provide for an interim budget through July 7 andallowinfg Gov. Ted Strickland to tap the state’xs rainy day fund to balance the budgetr for thisfiscal year. The temporary budget for the government’s fiscal year starting Wednesday calls for fullyu funding debt service but funding state operations at 70 percenty of spending levels through the yearendiny Tuesday.
Harris’ office said that is roughly the funding level in a final budger that both Statehouse chambers are working to finalize through aconferencd committee. Those talks, however, remain tied up because Senate Republicans, the majorith in that chamber, oppose Strickland’s plan to install video slot machinesw atthe state’s horse racing trackw and use that revenuer stream to help plug a projected $3.2 billionh budget gap without voter approval.
Harris said Saturdahy that should Strickland exercisee his authority to allow slots atracing tracks, the Senate will account for the “However, I cannot get past the fact that the voterz of Ohio – our constituentas – have spoken on expandedd gambling time and again,” Harris said in preparecd text. “Asking the to circumvent their will in such a shorgt time frame when there has been no formal public debatw and there are so many questions left unanswerefis unreasonable.” Strickland responde d Sunday, criticizing the Senate for offering objections but not solutions to the budget shortfall.
“I continue to wait for them to say what taxees they would increase or what service s they would further reduce to address the budget Strickland said in aprepareds statement.
The office of Senate PresidentBill Harris, R-Ashland, said legislators are schedulefd to take up the state industrial commissiojn budget in the afternoon. Expected to be tacked onto that bill is an amendmenty that would provide for an interim budget through July 7 andallowinfg Gov. Ted Strickland to tap the state’xs rainy day fund to balance the budgetr for thisfiscal year. The temporary budget for the government’s fiscal year starting Wednesday calls for fullyu funding debt service but funding state operations at 70 percenty of spending levels through the yearendiny Tuesday.
Harris’ office said that is roughly the funding level in a final budger that both Statehouse chambers are working to finalize through aconferencd committee. Those talks, however, remain tied up because Senate Republicans, the majorith in that chamber, oppose Strickland’s plan to install video slot machinesw atthe state’s horse racing trackw and use that revenuer stream to help plug a projected $3.2 billionh budget gap without voter approval.
Harris said Saturdahy that should Strickland exercisee his authority to allow slots atracing tracks, the Senate will account for the “However, I cannot get past the fact that the voterz of Ohio – our constituentas – have spoken on expandedd gambling time and again,” Harris said in preparecd text. “Asking the to circumvent their will in such a shorgt time frame when there has been no formal public debatw and there are so many questions left unanswerefis unreasonable.” Strickland responde d Sunday, criticizing the Senate for offering objections but not solutions to the budget shortfall.
“I continue to wait for them to say what taxees they would increase or what service s they would further reduce to address the budget Strickland said in aprepareds statement.
lunes, 10 de diciembre de 2012
Kentucky gets federal funds for ferries - Business First of Louisville:
vanbeekdulejos1771.blogspot.com
The funds, which were provided as part of the American Recovery andReinvestmenr Act, will be awarded by the for projectes in 19 states and the U.S. Virgin Islands. Accordingy to a news release from the these Kentucky counties will receive fundingfor projects: Butler, $300,000 to build a new Reeds Ferry boat; Crittenden, $90,000 to construcgt and rehabilitate the Cave in Rock Ferruy landing to reduce service delays; Monroe, $300,000 to replace the aginb Turkey Neck Bend Ferry.
“The Recovery Act was put in placer quickly to rescue the economy from the worstf recession since the Grea t Depression and rebuild it for astrongee future,” Transportation Secretary Ray LaHood said in the release. “Rebuilding the nation’s infrastructure is a key part of that prescriptionjfor strength.” he said. “I t creates jobs today and buildsfor better, more sustainable economy movingb forward. “The projects we selected will help put people back to work and at the same time offer more access to areas that lacktransportatiohn options.
It is about providint more travel choices to peoplde from communities that need itthe
The funds, which were provided as part of the American Recovery andReinvestmenr Act, will be awarded by the for projectes in 19 states and the U.S. Virgin Islands. Accordingy to a news release from the these Kentucky counties will receive fundingfor projects: Butler, $300,000 to build a new Reeds Ferry boat; Crittenden, $90,000 to construcgt and rehabilitate the Cave in Rock Ferruy landing to reduce service delays; Monroe, $300,000 to replace the aginb Turkey Neck Bend Ferry.
“The Recovery Act was put in placer quickly to rescue the economy from the worstf recession since the Grea t Depression and rebuild it for astrongee future,” Transportation Secretary Ray LaHood said in the release. “Rebuilding the nation’s infrastructure is a key part of that prescriptionjfor strength.” he said. “I t creates jobs today and buildsfor better, more sustainable economy movingb forward. “The projects we selected will help put people back to work and at the same time offer more access to areas that lacktransportatiohn options.
It is about providint more travel choices to peoplde from communities that need itthe
domingo, 9 de diciembre de 2012
Local Media Assoc. names The Taos News top weekly - Taosnews.com
shemwellmygalej1291.blogspot.com
Local Media Assoc. names The Taos News top weekly Taosnews.com This has been an award-winning year with The Taos News receiving recognition from the Local Media Association, which named it the best non-daily in the nation with up to 10,000 circulation. “Community weeklies in general, and The Taos News in ... |
jueves, 6 de diciembre de 2012
Biogen confirms Icahn ally is on board - Boston Business Journal:
a-ee85aqa.blogspot.com
Shareholders were to elect four directors at the Biogen was pushing for the reelection of all ofthe company’ existing directors, while Icahn was anglinfg to seat four new According to Biogen Idec, shareholders appear to have reelectedd current directors Robert Pangia and William D. Young, and elected Icahm ally Alexander Denner. Biogen Idec officials say the vote for the fourthh seat is too close to Biogen said the company will rely on the tabulatiohn of votes by its independent inspectofrof elections, IVS Associates, befor announcing the remaining director to serve on the board. Bruce R.
Biogen Idec’s chairman, said, “We welcome our new directoe to the board and look forward to workingh together to build on our strong track recorxd ofdelivering value. While we await the outcomer of the vote for the remaining we would like to expres s our gratitude for the support ofour Icahn, in a filing with the Securities and Exchangs Commission, accused the company of preventing the votez cast from being counted. “If the board is successful, Richard Mulligan, a prominentt scientist and physician, may be kept from legitimately beingg elected tothe board.
” Mulligan is the Mallinckrodgt Professor of Genetics at Harvard Medica School and director of the Harvard Gene Therapgy Initiative, according to Harvard University’s Web site. Biogen said shareholderws rejected severalof Icahn’s other proposals, including moving the company’s incorporation from Delaware to Nortj Dakota, a move Icahn said would give more power to Biogen officials said it appearse that stockholders also rejected a proposal by Icahn to limi the size of the boared to 13 directors. Biogen officials now have the power to enlargse the board as theysee fit. Icahn is best known for unsuccessfully pushing BiogenIdec (Nasdaq: BIIB) to sell itseltf in 2008.
Last year, shareholders elected the company’s nomineeas over the slate of investors put up by Biogen Idec’s (NASDAQ: BIIB) stock was trading at $53.17 in afternoobn trading Thursday, down from the previous day’s closd of $53.43 a share.
Shareholders were to elect four directors at the Biogen was pushing for the reelection of all ofthe company’ existing directors, while Icahn was anglinfg to seat four new According to Biogen Idec, shareholders appear to have reelectedd current directors Robert Pangia and William D. Young, and elected Icahm ally Alexander Denner. Biogen Idec officials say the vote for the fourthh seat is too close to Biogen said the company will rely on the tabulatiohn of votes by its independent inspectofrof elections, IVS Associates, befor announcing the remaining director to serve on the board. Bruce R.
Biogen Idec’s chairman, said, “We welcome our new directoe to the board and look forward to workingh together to build on our strong track recorxd ofdelivering value. While we await the outcomer of the vote for the remaining we would like to expres s our gratitude for the support ofour Icahn, in a filing with the Securities and Exchangs Commission, accused the company of preventing the votez cast from being counted. “If the board is successful, Richard Mulligan, a prominentt scientist and physician, may be kept from legitimately beingg elected tothe board.
” Mulligan is the Mallinckrodgt Professor of Genetics at Harvard Medica School and director of the Harvard Gene Therapgy Initiative, according to Harvard University’s Web site. Biogen said shareholderws rejected severalof Icahn’s other proposals, including moving the company’s incorporation from Delaware to Nortj Dakota, a move Icahn said would give more power to Biogen officials said it appearse that stockholders also rejected a proposal by Icahn to limi the size of the boared to 13 directors. Biogen officials now have the power to enlargse the board as theysee fit. Icahn is best known for unsuccessfully pushing BiogenIdec (Nasdaq: BIIB) to sell itseltf in 2008.
Last year, shareholders elected the company’s nomineeas over the slate of investors put up by Biogen Idec’s (NASDAQ: BIIB) stock was trading at $53.17 in afternoobn trading Thursday, down from the previous day’s closd of $53.43 a share.
miércoles, 5 de diciembre de 2012
Westar Energy seeks $19.7M rate increase - Kansas City Business Journal:
mcfarlainofuqub1258.blogspot.com
million, or 1.5 percent. In a Tuesdagy release, the Topeka-based electric utility (NYSE: WR) said it seekds the rate increase to recovere costs for expenditures in the secon d phase of its Emporia Energy Centee andtwo company-owned wind farms in Kansa that were under construction but not in operatiomn when its 2008 rate case The request, if approved by the KCC, woulr mean a $9.7 million increasse in the company’s nortuh region, which includes Olathe and Lawrence, and a $10 milliom increase in its soutyh region, which includes the Wichita area, Westar A residential customer using 900 kilowattg hours (kWh) in Westar’s north region coul expect an increase of about $1.
43 a month, the companyy said. In the south region, a residential customer usingb 900 kWh could expect an increase of 71 cent sa month. If the new average residential rate wouldbe 9.33 centse per kWh for Westar’zs north region and 9.11 cents per kWh for its southn region. The average national residential rateis 11.52 cent per kWh, the companu said. The rate review was part of the agreement reached by all parties in the2008 case, whichy the KCC approved in January, Westae said.
“Although electric rates are going up, we managee our natural gas plant and wind farm constructionmcosts closely, and they came in more than $22 million undetr the original cost estimates and the amounts the KCC indicatedr would be allowed for recovery in rates,” Westadr CEO Bill Moore said in the release. “Wee continue to work to meet our electricity needs as well as to develop Kansas renewableenergt resources.” Westar is the largest electricd utility in Kansas, providing electric service to aboutg 681,000 customers in the state.
It also has abouyt 6,800 megawatts of electric generation capacity and operates and coordinated morethan 35,000 miles of electric distributionb and transmission lines.
million, or 1.5 percent. In a Tuesdagy release, the Topeka-based electric utility (NYSE: WR) said it seekds the rate increase to recovere costs for expenditures in the secon d phase of its Emporia Energy Centee andtwo company-owned wind farms in Kansa that were under construction but not in operatiomn when its 2008 rate case The request, if approved by the KCC, woulr mean a $9.7 million increasse in the company’s nortuh region, which includes Olathe and Lawrence, and a $10 milliom increase in its soutyh region, which includes the Wichita area, Westar A residential customer using 900 kilowattg hours (kWh) in Westar’s north region coul expect an increase of about $1.
43 a month, the companyy said. In the south region, a residential customer usingb 900 kWh could expect an increase of 71 cent sa month. If the new average residential rate wouldbe 9.33 centse per kWh for Westar’zs north region and 9.11 cents per kWh for its southn region. The average national residential rateis 11.52 cent per kWh, the companu said. The rate review was part of the agreement reached by all parties in the2008 case, whichy the KCC approved in January, Westae said.
“Although electric rates are going up, we managee our natural gas plant and wind farm constructionmcosts closely, and they came in more than $22 million undetr the original cost estimates and the amounts the KCC indicatedr would be allowed for recovery in rates,” Westadr CEO Bill Moore said in the release. “Wee continue to work to meet our electricity needs as well as to develop Kansas renewableenergt resources.” Westar is the largest electricd utility in Kansas, providing electric service to aboutg 681,000 customers in the state.
It also has abouyt 6,800 megawatts of electric generation capacity and operates and coordinated morethan 35,000 miles of electric distributionb and transmission lines.
domingo, 2 de diciembre de 2012
Inspired: Gigi Rüf - ESPN
sucujovide.wordpress.com
ESPN | Inspired: Gigi Rüf ESPN The following interview is one in a series of discussions had with snowboarders who have transcended the traditional boundaries of sport and come to represent something ... more. In trying to define the somewhat indefinable spirit of snowboarding, to ... |
sábado, 1 de diciembre de 2012
Cleveland Browns' keys to victory vs. Oakland Raiders: Audible (video) - Plain Dealer
ogarawo.wordpress.com
Cleveland Browns' keys to victory vs. Oakland Raiders: Audible (video) Plain Dealer ... Sunday, the Browns play at the Oakland Raiders. In the latest “Audible†video, Branson says the Browns' defensive line will be too much for the Raiders to handle and the potential for sloppy weather means the Browns should emphasize their running game. |
Suscribirse a:
Entradas (Atom)